BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 2, 2026
Home » Keywords » inflammatory bowel disease

Items Tagged with 'inflammatory bowel disease'

ARTICLES

Illustration for inflammatory bowel disease
Gastrointestinal

Enveda’s ENV-6946 enters clinic for inflammatory bowel disease

Dec. 24, 2025
No Comments
Enveda has obtained IND clearance from the FDA and initiated a phase I trial of ENV-6946, a first-in-class oral small molecule for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Read More
Gastrointestinal

Numab and Kaken sign agreement for NM-81 for IBD

Nov. 14, 2025
No Comments
Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have entered into a strategic licensing and co-development agreement for NM-81, a multi-specific antibody for the treatment of inflammatory bowel disease (IBD).
Read More
Gastrointestinal

Interline Therapeutics patent reports RIPK2 inhibitors for IBD

Oct. 24, 2025
Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
Read More
Gastrointestinal

Salubris Pharmaceuticals divulges new MIR124 activators

Oct. 17, 2025
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized compounds acting as MIR124 activators reported to be useful for the treatment of inflammatory bowel disease and inflammatory disorders.
Read More
Gastrointestinal

ISM012-042 exerts protective effects in colitis model

Oct. 9, 2025
No Comments
A new study aimed to investigate the therapeutic effect of ISM012-042 in a chronic T-cell transfer-induced colitis model in mice that mimicked Crohn’s disease.
Read More
Gastrointestinal

Simcere reports preclinical data on bispecific antibody for IBD

Oct. 8, 2025
No Comments
Jiangsu Simcere Pharmaceutical Co. Ltd. reported on SIM-0709, a bispecific antibody.
Read More
Art concept for inflamed human tissue
Dermatologic

Arcus Biosciences announces new anti-inflammation programs

Oct. 7, 2025
No Comments
Arcus Biosciences Inc. has announced five new research programs for autoimmune and inflammatory diseases, and is targeting initiation of the first clinical studies next year.
Read More
Test tubes, dropper and capsules
Immune

Onco3r presents data on its best-in-class, selective SIK3 inhibitor

Oct. 7, 2025
No Comments
Researchers from Onco3r Therapeutics BV presented preclinical data on O3R-5671, a novel salt-inducible kinase 3 (SIK3) inhibitor developed for the treatment of inflammatory bowel disease and other autoimmune diseases.
Read More
Illustration of intestines with inflammation
Gastrointestinal

C4X Discovery selects oral α4β7 integrin inhibitor candidate

Sep. 23, 2025
No Comments
C4X Discovery Holdings Ltd. has selected a preclinical candidate from its oral α4β7 integrin inhibitor program for the treatment of inflammatory bowel disease (IBD). The potent and selective α4β7 inhibitor supports once-daily dosing. Moreover, the company’s approach can be combined with other targeted therapies for patients with complex or refractory disease where existing approaches have failed to deliver sufficient control.
Read More
Illustration of immunoglobulin A with secretory IgA
Gastrointestinal

NIH support for Lactiga’s sIgA antibody for IBD

Sep. 5, 2025
No Comments
Lactiga US Inc. has received an award from the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance the development of its secretory IgA (sIgA) antibody for inflammatory bowel disease (IBD).
Read More
More Articles Tagged with 'inflammatory bowel disease'

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • IMV-101 shows promise for B-cell malignancies

    BioWorld Science
    IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing